Overall, our observations of poor prognosis in patients with breast cancer with high EC-pY397-FAK expression levels alone or in combination with high BVD open new opportunities for enriching recruitment studies of novel therapeutics for this population. This evidence concerns the gene PTK2 and breast carcinoma.